Reports and Findings (Published Research)

COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years o

To address the urgent need for a vaccine for COVID-19, BioNet’s gene-based vaccine, COVIGEN, will be investigated in this first-in-human, Phase I study.

A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously primed with meningococcal ACWY vaccine (BOOST)

GSK is conducting a research study to evaluate its investigational, pentavalentmeningococcal vaccine, MenABCWY, which is based upon two licensed GSKmeningococcal vaccines, Menveo (MenACWY vaccine) and Bexsero (MenB vaccine).

A phase 3, randomized, double-blinded, placebo-controlled trial toevaluate the efficacy and safety of a respiratory syncytial virus (RSV) prefusion F subunit vaccine in infants born to women vaccinated during pregnancy (Matisse)

Respiratory syncytial virus (RSV) is a common, highly contagious virus that causes infections of the lungs and respiratory tract.

Safety and Immunogenicity of Early Quadrivalent Influenza Vaccine: A phase 2prospective randomised open-label feasibility study (FluBub)

Young children, particularly those younger than six (6) months are at increased riskof severe influenza infection.

A Phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infants (NeXXstep)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at Fremantle

A Phase I/II, Multicentre, Observer-blinded, Randomized, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a combined Tetanus, Diphtheria, Acellular Pertussis and Poliomyelitis Vaccine (SIIPL Tdap-IPV) in Compari

We are looking for children and teenagers to take part in an important study investigating the effectiveness of a new combination booster vaccine designed to protect against tetanus, diphtheria, pertussis (whooping cough) and polio.

A Phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults (Quintet)

The QUINTET Study will evaluate the effectiveness of a potential vaccine called MenABCWY.

Reducing the harm caused by radiation for children with brain cancer, including MRI evaluation of impacts of radiation therapy

Raelene Nick Endersby Gottardo BSc (Hons) PhD MBChB FRACP PhD Brainchild Fellow; Co-Head, Brain Tumour Research Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids

Anti-CD47 immunotherapy for medulloblastoma and high-grade glioma

Raelene Nick Endersby Gottardo BSc (Hons) PhD MBChB FRACP PhD Brainchild Fellow; Co-Head, Brain Tumour Research Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids

Developing and characterising juvenile models of aggressive paediatric brain cancers for the evaluation of novel immunotherapies

Nick Raelene Terrance Gottardo Endersby Johns MBChB FRACP PhD BSc (Hons) PhD Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia